Luca Alberici, MolMed Chief Business Officer, presenting at the 6th Annual ARM’s Cell & Gene Therapy Investor Day
New York City April, 17th 2018


Previous videos

Alliance for Regenerative Medicine,Luca Alberici, Ph.D, Business Development Director

Professor Mohamad Mohty (EBMT President) at the 58th Annual Meeting of the American Society of Hematology (ASH)

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.

Products of excellence

GMP Solutions

MolMed GMP Solutions provides tailor-made services for your cell & gene therapy projects.

Financial reports

First quarter interim report (in Italian) at 03/31/2018
Annual financial report at December 31, (in Italian) 2017
Interim financial report - in Italian, English translation to come at 09/30/2016
Half-year financial report -English translation for convenience at 06/30/2016

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | -
Privacy & Cookie Policy | Suppliers' Privacy Policy | Customers' Privacy Policy
Share capital € 21,819,020.83 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159